Enlivex Ltd. ENLV
Set alert
1.78 USD -0.76 -29.92%
At close · Oct 30
1.79 +0.01 +0.56%
After hours · Oct 30, 7:30 PM ET
1.73 Day range 2.47
0.173 52-week range 18.15
- YTD
- -83.13%
- 1 year
- -88.70%
- Open
- 2.47
- Prev close
- 2.54
- Mkt cap
- 2.73M
- Vol
- 128.30K
- Avg vol
- 65.51K
- EPS
- 7,904.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.73
- High
- 2.47
- Forward P/E
- -2.14
- Beta
- 1.10
- Short ratio
- 0.56
- Inst. own
- 18.81%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.27
- 200-d avg
- 1.67
- 1y target
- 9.50
5D chart
Events in this range
- Oct 27, 2026Split: 1 for 16
Signals (87)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 11:20 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 11:20 AM | 1 day ago |
| SMA: Bearish | Oct 29, 3:40 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:40 PM | 2 days ago |
| RSI: Oversold | Oct 29, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:40 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:05 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 10:00 AM | 2 days ago |
| RSI: Oversold | Oct 29, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 28, 3:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:50 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 3 days ago |
| RSI: Overbought | Oct 28, 1:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 3 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 11:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 11:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:40 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 4 days ago |
| RSI: Oversold | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 5 days ago |
| RSI: Overbought | Oct 26, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:55 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 5 days ago |
Key statistics
- Market cap
- 27.27M
- Enterprise value
- -1.30M
- Trailing P/E
- 0.00
- Forward P/E
- -2.14
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.77
- EPS (TTM)
- -0.98
- Beta
- 1.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -11.98M
- Total cash
- 25.94M
- Total debt
- 835.00K
- Return on equity
- -61.17%
- Shares outstanding
- 21.99M
- Short % of float
- 0.49%
- 50-day average
- 1.27
- 200-day average
- 1.67
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 9.50 +433.7% upside
Now 1.78
- Target (low)
- 6.00
- Target (mean)
- 9.50
- Target (high)
- 13.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.16.
Financials — quick view
ENLV Revenue — quarterly 0
ENLV Net income — quarterly 1.89B
ENLV EPS — quarterly 1,830.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 29, 2024 | Sep 1, 2024 | -0.16 | -0.12 | +0.04 | +25.00% |
| Aug 30, 2024 | Jun 1, 2024 | -0.22 | -0.16 | +0.06 | +27.27% |
| Jun 14, 2024 | Mar 1, 2024 | -0.25 | -0.22 | +0.03 | +12.00% |
| Mar 29, 2024 | Dec 1, 2023 | 0.00 | -0.48 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -0.32 | -0.32 | 0.00 | 0.00% |
| Sep 1, 2023 | Jun 1, 2023 | -0.43 | -0.37 | +0.06 | +13.95% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | D. Boral Capital | main | Buy | Buy |
| Dec 3, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 14, 2024 | D. Boral Capital | main | Buy | Buy |
| Sep 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 26, 2024 | EF Hutton | main | Buy | Buy |
| Sep 24, 2024 | EF Hutton | main | Buy | Buy |
About Enlivex Ltd.
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- enlivex.com
News
- Enlivex Reports 135 Of 182 Planned Patients Randomized And Dosed In Phase 2b Knee Osteoarthritis Trial Of Allocetra; Topline Six-Month Data Expected By Mid-2027
- Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
- Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
- Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
- Enlivex Reveals 1-For-16 Reverse Share Split To be Effective October 27, 2026
- Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Enlivex Launches Cost Reduction Plan To Prioritize Phase 2b Allocetra Knee Osteoarthritis Trial, Topline Data Expected By Mid-2027
- Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
- 12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on ENLV — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 11.52% | 2,139,000 | 2.65M | Sep 29, 2024 |
| Morgan Stanley | 1.32% | 245,754 | 304.73K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.40% | 74,789 | 92.74K | Sep 29, 2024 |
| Sigma Investment Counselors Inc | 0.16% | 30,000 | 37.20K | Sep 29, 2024 |
| Xtx Topco Ltd | 0.12% | 22,659 | 28.10K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.08% | 13,935 | 17.28K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 10,420 | 12.92K | Oct 30, 2024 |